Elsevier

Human Pathology

Volume 33, Issue 1, January 2002, Pages 60-67
Human Pathology

Original Contributions
MUC1 mucin and trefoil factor 1 protein expression in renal cell carcinoma: Correlation with prognosis*

https://doi.org/10.1053/hupa.2002.29682Get rights and content

Abstract

This study examines the coexpression of MUC1 mucin and trefoil factor 1 (TFF1) and their relationship to progression of renal cell carcinoma (RCC). Immunohistochemistry was performed on tumor and adjacent normal tissue from clear-cell RCC (n = 60) and tissues from normal controls (n = 5) using a set of well-characterized monoclonal antibodies recognizing different epitopes of MUC1 and TFF1. Results of immunohistochemistry were compared with clinical parameters, including tumor grade, tumor size, presence of metastasis, and progression-free survival of patients after surgery. In normal tissue, MUC1 and TFF1 were absent from the normal proximal tubular epithelium but were identified in distal and collecting tubular epithelium. In RCC, increased MUC1 expression positively correlated to tumor progression. MUC1 recognized by HMFG1 was associated with large tumor size (P <.05), distant metastasis (P <.05), and invasion of large veins (P <.05). Expression of the under-glycosylated form of MUC1 recognized by SM3 was found to correlate to time to progression (recurrence, metastasis, or death of patient; P <.001). Expression of TFF1 did not significantly correlate with any prognostic parameters. However, there was a significant correlation (P <.01) between TFF1 and MUC1 expression (HMFG2 epitope) in RCCs. These results are consistent with the following conclusions: (1) MUC1 may be an independent prognostic marker in RCC; (2) TFF1 is frequently coexpressed with MUC1 and may act synergistically; and (3) RCC may originate from distal tubular epithelium. HUM PATHOL 33:60-67. Copyright © 2002 by W.B. Saunders Company

Section snippets

Patient data

Sixty samples of RCC from patients who had under gone radical nephrectomy and 5 samples of normal kidney (obtained after nephrectomy for acute trauma) were studied. The mean age of patients with RCC was 69.5 (range, 37 to 92) years; 39 were male, and 21 were female. Clinical follow-up was available for 53 of the patients, providing data on disease-free survival (DFS) for this group (DFS 0, no evidence of disease; DFS 1, disease recurrence or tumor-associated death). Mean follow-up time was 29.7

Results

Results of IHC in RCCs are summarized in Table 1.

Discussion

Although there is a large body of evidence implicating MUC1 in the progression of human adenocarcinomas, only 2 previous reports have sought to correlate MUC1 with clinical outcome in renal cancer.23, 24 Given that the glycosylation status of the MUC1 tandem repeat can profoudly alter antibody epitope recognition, we used 3 different antibodies that recognize overlapping epitopes but have different sensitivities to glycosylation status. We have shown that the expression of MUC1 (HMFG1 and

References (49)

  • S Ribieras et al.

    The pS2/TFF1 trefoil factor, from basic research to clinical applications

    Biochim Biophys Acta

    (1998)
  • KH Jorgensen et al.

    Pancreatic spasmolytic polypeptide (PSP): I. Preparation and initial chemical characterization of a new polypeptide from porcine pancreas

    Regul Pept

    (1982)
  • L Thim

    A new family of growth factor-like peptides. "Trefoil' disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spasmolysins)

    FEBS Lett

    (1989)
  • R Williams et al.

    Characterization of monoclonal antibodies raised to C-terminal peptides of pS2: A major trefoil peptide and motility factor expressed in adenocarcinomas and regions of mucosal injury

    Hum Pathol

    (1996)
  • R Metzger et al.

    Angiotensin-converting enzyme in non-neoplastic kidney diseases

    Kidney Int

    (1999)
  • M Yamamoto et al.

    Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion

    J Biol Chem

    (1997)
  • H Kindon et al.

    Trefoil peptide protection of intestinal epithelial barrier function: Cooperative interaction with mucin glycoprotein

    Gastroenterology

    (1995)
  • JR Franklin et al.

    Renal cell carcinoma: Basic biology and clinical behavior

    Semin Urol Oncol

    (1996)
  • E Seregni et al.

    Structure, function and gene expression of epithelial mucins

    Tumori

    (1997)
  • E Lagow et al.

    Mammalian reproductive tract mucins

    Hum Reprod Update

    (1999)
  • FG Hanisch et al.

    MUC1: The polymorphic appearance of a human mucin

    Glycobiology

    (2000)
  • J Wesseling et al.

    Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components

    J Cell Biol

    (1995)
  • J Wesseling et al.

    A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1

    Mol Biol Cell

    (1996)
  • M Hartman et al.

    MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer

    Int J Cancer

    (1999)

    • Cited by (53)

    • Trefoil factor 3: New highlights in chronic kidney disease research

      2022, Cellular Signalling

    • Autosomal Dominant Tubulointerstitial Kidney Disease Due to MUC1 Mutation

      2018, American Journal of Kidney Diseases
      Citation Excerpt :

      As demonstrated in the sibling of the case(s) discussed here, there are kidney biopsy findings in the setting of a CTIN that may suggest the diagnosis of ADTKD, such as TBM thickening and thinning, an irregular branching tubular architecture, and cyst formation, but these findings are subtle and inconsistently seen, even in a single kindred. Mucin 1 (MUC-1) is one of the human mucin proteins, functioning as a transmembrane glycoprotein involved in cell-cell interaction with intracellular signal transduction by the cytoplasmic tail.15 In rodent models of kidney ischemia-reperfusion injury, MUC-1 has been found to enhance both HIF-1 (hypoxia inducible factor 1) and β-catenin–dependent pathways, 2 important protective cellular pathways.16,17

    • Autosomal dominant tubulointerstitial kidney disease: Diagnosis, classification, and management - A KDIGO consensus report

      2015, Kidney International

    • Host response in tumor diagnosis and prognosis: Importance of immunologists and pathologists alliance

      2012, Experimental and Molecular Pathology
      Citation Excerpt :

      One of the better known is antibody CA15-3 almost exclusively used in breast cancer diagnosis, even though MUC1 is expressed in all adenocarcinomas and could be useful in other diagnoses where it often shows superiority over other established biomarkers (Sangoi et al., 2009; Winter et al., 2012). Differential expression of MUC1 has also been linked to prognosis (Baldus et al., 2002; Kraus et al., 2002; Leroy et al., 2002; Sagara et al., 1999; Sivridis et al., 2002). There is also evidence that MUC1 enhances the metastatic abilities of tumor cells (Guddo et al., 1998; Hiraga et al., 1998).

    • Mucin 1 expression correlation with lymph node metastasis and micrometastasis and poor prognosis in patients with esophageal squamous cell carcinomas

      2023, Archives of Medical Science

    • Genetic Susceptibility to Chronic Kidney Disease: Links, Risks and Management

      2023, International Journal of Nephrology and Renovascular Disease
    View all citing articles on Scopus
    *

    Address correspondence and reprint requests to El-Nasir Lalani, FRCPath, Department of Histopathology, Imperial College School of Medicine, Hammersmith Hospital, London W12 0NN, England.

    View full text
    Copyright © 2002 W.B. Saunders Company. Published by Elsevier Inc. All rights reserved.